135 related articles for article (PubMed ID: 38503370)
1. Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.
Harada M; Han S; Shi M; Ge J; Yu S; Adam J; Adamski J; Scheerer MF; Neschen S; de Angelis MH; Wang-Sattler R
Int J Biol Macromol; 2024 Apr; 265(Pt 1):130962. PubMed ID: 38503370
[TBL] [Abstract][Full Text] [Related]
2. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i.
Harada M; Adam J; Covic M; Ge J; Brandmaier S; Muschet C; Huang J; Han S; Rommel M; Rotter M; Heier M; Mohney RP; Krumsiek J; Kastenmüller G; Rathmann W; Zou Z; Zukunft S; Scheerer MF; Neschen S; Adamski J; Gieger C; Peters A; Ankerst DP; Meitinger T; Alderete TL; de Angelis MH; Suhre K; Wang-Sattler R
Cardiovasc Diabetol; 2024 Jun; 23(1):199. PubMed ID: 38867314
[TBL] [Abstract][Full Text] [Related]
3. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
Neschen S; Scheerer M; Seelig A; Huypens P; Schultheiss J; Wu M; Wurst W; Rathkolb B; Suhre K; Wolf E; Beckers J; Hrabé de Angelis M
Diabetes; 2015 Jan; 64(1):284-90. PubMed ID: 25071027
[TBL] [Abstract][Full Text] [Related]
4. The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes.
Linden MA; Ross TT; Beebe DA; Gorgoglione MF; Hamilton KL; Miller BF; Braun B; Esler WP
Metabolism; 2019 Aug; 97():68-80. PubMed ID: 31132381
[TBL] [Abstract][Full Text] [Related]
5. A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor.
Fujita Y; Atageldiyeva KK; Takeda Y; Yanagimachi T; Makino Y; Haneda M
Front Endocrinol (Lausanne); 2020; 11():601594. PubMed ID: 33362717
[TBL] [Abstract][Full Text] [Related]
6. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk.
Kim JH; Lee M; Kim SH; Kim SR; Lee BW; Kang ES; Cha BS; Cho JW; Lee YH
Diabetes Obes Metab; 2019 Apr; 21(4):801-811. PubMed ID: 30407726
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
9. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
10. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K; Segar L
Eur J Pharmacol; 2019 Mar; 846():23-29. PubMed ID: 30639796
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
Nazari S; Mirkhani H
Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Communication by SGLT2 Inhibition.
Billing AM; Kim YC; Gullaksen S; Schrage B; Raabe J; Hutzfeldt A; Demir F; Kovalenko E; Lassé M; Dugourd A; Fallegger R; Klampe B; Jaegers J; Li Q; Kravtsova O; Crespo-Masip M; Palermo A; Fenton RA; Hoxha E; Blankenberg S; Kirchhof P; Huber TB; Laugesen E; Zeller T; Chrysopoulou M; Saez-Rodriguez J; Magnussen C; Eschenhagen T; Staruschenko A; Siuzdak G; Poulsen PL; Schwab C; Cuello F; Vallon V; Rinschen MM
Circulation; 2024 Mar; 149(11):860-884. PubMed ID: 38152989
[TBL] [Abstract][Full Text] [Related]
15. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
17. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
Wong CKH; Lau KTK; Tang EHM; Lee CH; Lee CYY; Woo YC; Au ICH; Tan KCB; Lui DTW
Cardiovasc Diabetol; 2022 Jun; 21(1):92. PubMed ID: 35658864
[TBL] [Abstract][Full Text] [Related]
19. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies.
Ma Y; Zhao Q; Peng H; Nalisa DL; Shan P; Jiang H
Front Biosci (Landmark Ed); 2023 May; 28(5):98. PubMed ID: 37258468
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
Koufakis T; Papazafiropoulou A; Makrilakis K; Kotsa K
Cardiovasc Drugs Ther; 2023 Apr; 37(2):315-321. PubMed ID: 34476668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
